Loading
Mycophenolate Mofetil · Regulatory label update
U.S. Food and Drug Administration · July 29, 2026
The material analysed did not support any firm read.
The FDA approved a supplemental application (ANDA214079) for a Risk Evaluation and Mitigation Strategy (REMS) for mycophenolate mofetil 250 mg capsules on 29 July 2026. This is a regulatory action establishing risk management requirements; it does not contain clinical trial data, efficacy comparisons, or safety study results.
Regulatory label update.
The FDA approved a supplemental application (ANDA214079) for a Risk Evaluation and Mitigation Strategy (REMS) for mycophenolate mofetil 250 mg capsules on 29 July 2026. This is a regulatory action establishing risk management requirements; it does not contain clinical trial data, efficacy comparisons, or safety study results.
This record does not contain clinical trial results, efficacy data, or comparative safety evidence. No safety signals, adverse event data, or rationale for the REMS approval are provided.
Clinicians and pharmacists should be aware that mycophenolate mofetil is subject to FDA-mandated REMS requirements that govern distribution, dispensing, and patient counselling. Consult the approved REMS document for specific program obligations and restrictions.
FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for mycophenolate mofetil; regulatory action establishing safety management requirements, not clinical efficacy evidence.
Clinicians and pharmacists should be aware that mycophenolate mofetil is subject to FDA-mandated REMS requirements that govern distribution, dispensing, and patient counselling. Consult the approved REMS document for specific program obligations and restrictions.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings, reported figures. That is a gap in the analysis, not a judgement about the study.
Drugs@FDA record for application ANDA214079. This is a regulatory action record, not a clinical study. Brand name: MYCOPHENOLATE MOFETIL. Active ingredient: MYCOPHENOLATE MOFETIL. Sponsor: WUXI. Submission type: SUPPL (supplement). Submission class: REMS. Approval status date: 2026-07-29. Products: MYCOPHENOLATE MOFETIL, CAPSULE, ORAL, MYCOPHENOLATE MOFETIL 250MG.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.